Take a look through some of the notable data presentations at this year's ESMO Congress.
Commentary|Videos|May 30, 2026
Rana McKay, MD, on radium-223 plus cabozantinib in renal cell carcinoma
Author(s)Rana R. McKay, MD
Fact checked by: Hannah Clarke, Tracy Ann Politowicz
Rana R. McKay, MD, FASCO, highlights phase 2 data on radium-223 dichloride plus cabozantinib for patients with renal cell carcinoma with bone metastases.
Advertisement
In the following interview, conducted at the
Advertisement
Related to this article
The investigational HIF-2α inhibitor casdatifan demonstrated antitumor activity as monotherapy and in combination regimens across the ARC-20 platform study.
Jeffrey M. Spier, MD, reviews evidence on ARPI dose reduction in prostate cancer and discusses monitoring treatment response, tolerability, and dose reescalation.
Jeffrey M. Spier, MD, discusses managing ARPI-related fatigue through dose adjustments, patient monitoring, and strategies to maintain treatment adherence.
Sandip M. Prasad, MD, MPhil, discusses the safety profile of mitomycin intravesical solution, including common adverse events and patient counseling during chemoablation for NMIBC.
Sandip M. Prasad, MD, MPhil, discusses 3-year ENVISION trial data showing durable responses with mitomycin intravesical solution for recurrent LG-IR-NMIBC.
Armine K. Smith, MD, discusses sexual health counseling, sex-specific considerations, and organ-preserving approaches for patients undergoing radical cystectomy.
Melissa Hadley Barrett discusses real-world outcomes and tolerability of intranasal vardenafil for men with persistent erectile dysfunction despite prior standard therapy.
Advertisement
Advertisement
Trending on Urology Times
1
ESMO 2026: Key presentations across genitourinary oncology
2
FDA accepts new drug application for UGN-103 in recurrent LG-IR-NMIBC
3
Casdatifan shows activity across treatment settings in advanced ccRCC
4
Jeffrey M. Spier, MD, on the evidence for reduced-dose enzalutamide
5